Deoxyspergualin

Generic Name: Deoxyspergualin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₃₇N_₇O_₃

CAS Number: 89149-10-0

Unique Ingredient Identifier: 57F9XM233R

Background: Deoxyspergualin has been used in trials studying the treatment of Lupus Nephritis, Chronic Rejection, and Diabetes Mellitus, Type 1.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection

Not Applicable

Terminated

Conditions: Chronic Rejection

Interventions: Drug: Deoxyspergualin

First Posted Date: 2010-01-20

Last Posted Date: 2014-01-08

Lead Sponsor: Nippon Kayaku Co., Ltd.

Target Recruit Count: 35

Registration Number: NCT01052259

Locations: 🇯🇵
Gifu University Graduate School of Medicine, Gifu, Japan
🇯🇵
Graduate School of Medicine Sciences, Kyushu University, Fukuoka, Japan
🇯🇵
Sapporo City General Hospital, Sapporo, Hokkaido, Japan

and more 5 locations

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Allogeneic Pancreatic Islet Cells
Drug: Deoxyspergualin
Biological: Antithymocyte globulin
Biological: Daclizumab or basiliximab
Drug: Sirolimus
Drug: Tacrolimus
Biological: Etanercept

First Posted Date: 2007-02-13

Last Posted Date: 2016-03-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT00434850

Locations: 🇺🇸
University of Californinia, San Francisco, San Francisco, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy